Michael Rossi: Well, Robert, thank you for the question. As we are looking at these safety studies and moving forward on a new platform on specific targeting, we are going to be able to really work with these to tailor make what that response looks like, and also leveling out what some of the patient individual responses look like. I will pass it to the scene for some additional color. But as we look at these, our primarily goal now is to balance the safety and then move into the efficacy as we move forward with the clinical trials. Steen?
Steen Lisby: Thank you, Mike, and I think I had not much more to add to this because what is really, it is important for us now, and the potential benefit of the SADA platform is that you administer the radioactive nucle when the majority of free protein is out of the system. So the whole goal here is to differentiate from the one step radio nucle out there in order for us to spare normal tissue. And then we see from there on how much we can add onto the tumors based on that data.
Robert Burns: Awesome, thank you. Second follow-up from me. So when we think about the CD38 SADA, specifically in the multiple myeloma context, what are you viewing as the benchmark there? Are you viewing the benchmark as just what DARZALEX did back in the day or are you looking at these new CD38 targeted agents like Moderna Fast Alpha and Hexa Body CD38? And then are you also enabling prior DARZALEX utilization in those patient populations?
Michael Rossi: Robert, thank you for your question on that, and I will pass that over to Steen for what the plans are for the Phase 1 and as we move forward.
Steen Lisby: So as discussed earlier on this call, we are starting the Phase 1 program in non-Hodgkin lymphoma. So we are actually not dosing multiple myeloma initially, and that’s in order for us to quite quickly create the safety benefit of that molecule. And I do agree that there is a lot of competition on a CD38 molecule, but this is predominantly in multiple myeloma space, and I think what we do have here is completely different mode of action as compared to the competitors. So I’m not quite confident we will later go there, but we will initially start the development plan to start the development here in the both the B and T cell space in not Hodgkin lymphoma.
Operator: This concludes our question-and-answer session. I would like to turn the floor back over to Mike Rossi for closing comments.
Michael Rossi: Thank you, operator, and thank you everyone for your participation on today’s third quarter earnings call and for your continued interest in Y-mAbs. We believe we are in a strong position as we work to deliver multiple potential value-creating milestones with our novel SADA technology, while continuing to drive adoption, growth and expansion of the DANYELZA franchise. Let me say it again, I’m thrilled to be part of this special company and look forward to working as one team with a patient-first mindset in our mission to fight cancer. Thank you everyone and have a great day.
Operator: This concludes today’s teleconference. You may disconnect your lines at this time. Thank you for your participation.
